The diagnostics industry is constantly under pressure to bring innovation quicker to market and so the impetus to speed up product-development cycle times becomes greater. There are a number of steps in the product-development cycle where the application of high-throughput screening can help. In the case of lateral-flow immunodiagnostics the selection of antibody reagents is paramount. In particular, rapid identification of antibody pairs that are able to ' sandwich ' around the target antigen is required. One screen that has been applied successfully is the use of surface plasmon resonance biosensors like Biacore2. Using such a system one can evaluate over 400 antibody pairings in under 5 days. Conventional approaches to screen this number of antibody pairs would take many months. Other automated screening systems like DELFIA2 can be used in processing the vast amount of tests required for clinical trials. In addition, the use of robotics to automate routine product testing can be used to shorten the product-development cycle.
When the consumer-diagnostic market took off in the mid-1980s one of the first tests on the market was the pregnancy test. The introduction of the lateral-flow pregnancy test by Unipath in 1988 demonstrated that the introduction of radical technology that met the consumer need could quickly establish a leading market position. Since that time there have been a number of lateral-flow rapid assay tests introduced into a number of markets by a number of companies.
Lateral assay flow technology typically relies on the migration of particles along a porous medium such as nitrocellulose (see Figure 1a) . A monoclonal antibody is adsorbed at a line on the nitrocellulose and a second monoclonal antibody is adsorbed on the particle. Therefore, in the presence of analyte the moving particle is arrested at the antibody line on the nitrocellulose as it is the Key words : consumer diagnostics, Biacore2, DELFIA2, robotics. Abbreviation used : HTS, high-throughput screening. 1 E-mail steve.howell!unipath.com analyte that provides a bridge (see Figure 1b) . In the absence of analyte no bridge is formed and the particle is allowed to track past the adsorbed antibody line unhindered. One can see that the selection of antibody pairs in this type of system is crucial. If the selected pair of antibodies bind to overlapping epitopes then this is problematic as a reduced or even no signal is produced.
When one considers the development cycle of a diagnostic (see Figure 2 ) it is apparent that anything that can reduce time to market would be beneficial. Three areas where high-throughput screening (HTS) can play a part are market discovery, reagent development and product optimization.
The use of HTS in marker discovery
It is important to base a diagnostic on a marker that is clinically relevant. Establishing clinical utility of potential markers requires the use of quantitative screening assays that must be flexible and capable of a high throughput. One commercially available instrument that is widely used is DELFIA2 (PerkinElmer Life Sciences). Using such approaches has enabled a variety of assays to be established (for example, the detection of bovine spongiform encephalopathy [1] ). We have used DELFIA2 to set up four in-house assays and have been able to screen over 500 000 samples (J. Coley, personal communication). However, one must not ignore the cost of undertaking such studies as the overall cost per test can be as high as £1.
Once markers have been identified using ' gold standard ' assay platforms they can then be taken forward and assay formats designed for use in consumer-based diagnostics. Hence, it is only after a marker has been selected that the rest of the product-development cycle can begin. Shortening the time to marker selection through the use of HTS systems such as DELFIA2 reduces this development cycle.
The use of HTS in reagent development
As described previously, there are a number of lateral-flow-based assays in the marketplace and many of these use antibody pairs as part of the 
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Development cycle of a diagnostic
Figure 3
Screening antibody pairings using Biacore2 technology A sensor surface is created with an anti-mouse antibody covalently coupled to a CM-dextran sensor chip (CM5). This is used as the basis for capturing the first antibody of the pair (LH MAb1) and a corresponding mass increase is detected on the instrument. Following a subsequent step to block excess antibody sites the antigen is introduced into the system (LH Antigen) again with a concomitant increase in mass detected. The second antibody pairing is introduced (LH MAb2) and the sensor response is used to determine how well both antibodies pair.
assay format (see Figure 1) . It has been possible to use automated instruments such as Biacore2 to select antibodies that pair around an analyte molecule [2] . Biacore2 uses surface plasmon resonace (SPR) to probe refractive index changes occurring near to a metal surface. Increases in mass close to this surface result in refractive index changes that can be detected with the instrument. Using such a system it is possible to set up capture assays as shown in Figure 3 . Here, sequential addition of reagents is detected as increasing mass at the sensor surface. The mass change is directly related to the amount of material binding and so it is possible to rank how well antibodies pair around the analyte.
If one has say 20 antibodies from which to select a pairing there are a possible 400 (20i20) combinations. A conventional approach would be to prepare 20 nitrocellulose samples and 20 latex samples where each has one antibody type adsorbed on their respective surfaces. One would then set about testing all 400 combinations. This would entail up to 3-6 months of testing. However, using Biacore2 one can set up an approach as shown in Figure 3 and short-list candidates within 5 days. Focus can then be given to these shortlisted candidates, thus accelerating the development cycle.
The use of HTS in product optimization
Once a working assay format has been established it is then necessary to optimize the system. This can take the form of identifying optimal ionic strength, pH, blocking conditions or indeed many other parameters. In order to reduce product-
Figure 4
Automated robotic system for testing assay devices optimization time robotics has been used. In this situation complete assay systems can be run where a robotic arm is programmed to sample devices, leave them for a set running time and then read the devices. Using a CRS 7 joint robot arm it has been possible to set up an automated system capable of assaying eight devices\min for 24 h per day (see Figure 4) . This approach reduces resource requirements and increases throughput 6-fold.
Summary
The use of HTS systems at various stages in the product-development cycle can dramatically
Introduction
In the last few years, the pharmaceutical industry has relied heavily on high-throughput screening (HTS) technology for the identification of hits. Large investments and logistic efforts have been put into setting up robotic equipment and in acquiring, assembling and maintaining big corporate compound collections. Within this period, HTS has indeed been able to prove itself as a technology capable of supplying novel valuable hits to our drug-discovery pipelines. However, alongside its now established value, it has been widely recognized that the assay-to-lead attrition rate is higher than initially anticipated and that, Key words : flexible superposition, hit identification, oestrogen receptor α. Abbreviations used : HTS, high-throughput screening ; ACD, Available Chemicals Directory. 1 E-mail j.mestres!organon.nhe.akzonobel.nl speed up the time to market for a new product. Many industries are under commercial pressure to innovate and bring products to market quickly. Where as new drugs can have lifetimes of over 15 years many consumer products typically have shorter product lifetimes. Therefore, a short product-development cycle is essential for consumer-based products.
even in those cases where leads are generated from hit-optimization programmes, the quantity, quality and diversity of those leads have been below original expectations [1] . In addition, a number of important quality issues have emerged, namely, quality of the assays (leading often to poor quality of data, large numbers of false positives and tedious active confirmation process), quality of the collection (purity and stability of compounds, as well as composition and origin of the collection) and quality of the logistics (purchase, tracking, handling and storage of compounds and data management), which have increased significantly the cost of maintenance of HTS.
In spite of the relatively low hit rates and the quality issues highlighted above, HTS is still considered nowadays to be the main source of hits in pharmaceutical companies. However, at the same time, it has become apparent that other techniques and\or strategies for hit identification are needed to keep up with current demands in drug discovery. Within this scenario, computational methods for the virtual screening of compound libraries offer a time-efficient and cost-effective alternative or complement to HTS [2] .
Virtual screening
Virtual screening can be defined as the process of reducing a library containing an unmanageable number of compounds (available or virtual) to a limited number of potentially promising compounds for the target (or target family) of interest by means of computational methods that exploit
